TipRanks
Abivax SA (DE:2X1)
XETRA:2X1
Germany Market

Abivax SA (2X1) Stock Forecast & Price Target

4 Followers
See the Price Targets and Ratings of:

2X1 Analyst Ratings

Moderate Buy
1Ratings
Moderate Buy
1 Buy
0 Hold
0 Sell
Based on 1 analysts giving stock ratings to
Abivax
SA
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

2X1 Stock 12 Month Forecast

Average Price Target

€132.00
▲(34.97% Upside)
Based on 1 Wall Street analysts offering 12 month price targets for Abivax SA in the last 3 months. The average price target is €132.00 with a high forecast of €132.00 and a low forecast of €132.00. The average price target represents a 34.97% change from the last price of €97.80.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"67":"€67","100":"€100","133":"€133","83.5":"€83.5","116.5":"€116.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":132,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€132.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":132,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€132.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":132,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€132.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[67,83.5,100,116.5,133],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,98.45,101.03076923076924,103.61153846153846,106.1923076923077,108.77307692307693,111.35384615384615,113.93461538461538,116.51538461538462,119.09615384615384,121.67692307692307,124.25769230769231,126.83846153846153,129.41923076923078,{"y":132,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,98.45,101.03076923076924,103.61153846153846,106.1923076923077,108.77307692307693,111.35384615384615,113.93461538461538,116.51538461538462,119.09615384615384,121.67692307692307,124.25769230769231,126.83846153846153,129.41923076923078,{"y":132,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,98.45,101.03076923076924,103.61153846153846,106.1923076923077,108.77307692307693,111.35384615384615,113.93461538461538,116.51538461538462,119.09615384615384,121.67692307692307,124.25769230769231,126.83846153846153,129.41923076923078,{"y":132,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":68.4,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.5,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90.7,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":106.4,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":120.6,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":93.5,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":99.3,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101.8,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":96.35,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":110.9,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":117.1,"date":1782864000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":106.2,"date":1785542400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":98.45,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€132.00Average Price Target€132.00Lowest Price Target€132.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Goldman Sachs Analyst forecast on DE:2X1
Goldman Sachs
Goldman Sachs
€132
Buy
34.97%
Upside
Initiated
09/09/26
Abivax SA (0RA9) Has a New Rating from Goldman Sachs
Kepler Capital  Analyst forecast on DE:2X1
Kepler Capital
Kepler Capital
€130
Buy
32.92%
Upside
Reiterated
04/13/26
Kepler Capital Keeps Their Buy Rating on Abivax SA (0RA9)
Oddo BHF
€88→€120
Buy
22.70%
Upside
Reiterated
04/09/26
Abivax price target raised to EUR 120 from EUR 88 at Oddo BHFAbivax price target raised to EUR 120 from EUR 88 at Oddo BHF
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Goldman Sachs Analyst forecast on DE:2X1
Goldman Sachs
Goldman Sachs
€132
Buy
34.97%
Upside
Initiated
09/09/26
Abivax SA (0RA9) Has a New Rating from Goldman Sachs
Kepler Capital  Analyst forecast on DE:2X1
Kepler Capital
Kepler Capital
€130
Buy
32.92%
Upside
Reiterated
04/13/26
Kepler Capital Keeps Their Buy Rating on Abivax SA (0RA9)
Oddo BHF
€88→€120
Buy
22.70%
Upside
Reiterated
04/09/26
Abivax price target raised to EUR 120 from EUR 88 at Oddo BHFAbivax price target raised to EUR 120 from EUR 88 at Oddo BHF
Stocks with the Highest Top Analyst Consensus in the General Sector
STDNStandard Nuclear
SKHYSK Hynix
ITGITG Inc. Class A
LIMENeutron Holdings, Inc.
EROCERock
Find stocks in the General sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Abivax SA

3 Months
Justine TelliezKepler Capital
Success Rate
12/25 ratings generated profit
48%
Average Return
+66.68%
Copying Justine Telliez's trades and holding each position for 3 Months would result in 48.00% of your transactions generating a profit, with an average return of +66.68% per trade.
1 Year
Justine TelliezKepler Capital
Success Rate
12/25 ratings generated profit
48%
Average Return
+220.85%
Copying Justine Telliez's trades and holding each position for 1 Year would result in 48.00% of your transactions generating a profit, with an average return of +220.85% per trade.
2 Years
Justine TelliezKepler Capital
Success Rate
17/25 ratings generated profit
68%
Average Return
+398.88%
Copying Justine Telliez's trades and holding each position for 2 Years would result in 68.00% of your transactions generating a profit, with an average return of +398.88% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

2X1 Analyst Recommendation Trends

Rating
May 26
Jun 26
Jul 26
Aug 26
Sep 26
Strong Buy
0
0
0
0
0
Buy
3
2
0
0
1
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
3
2
0
0
1
In the current month, 2X1 has received 1 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 2X1 average Analyst price target in the past 3 months is 132.00.
Each month's total comprises the sum of three months' worth of ratings.

2X1 Financial Forecast

2X1 Earnings Forecast

Next quarter’s earnings estimate for 2X1 is -€0.86 with a range of -€1.26 to -€0.53. The previous quarter’s EPS was -€1.47. 2X1 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 50.49% of the time in the same period. In the last calendar year 2X1 has Performed in-line its overall industry.
Next quarter’s earnings estimate for 2X1 is -€0.86 with a range of -€1.26 to -€0.53. The previous quarter’s EPS was -€1.47. 2X1 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 50.49% of the time in the same period. In the last calendar year 2X1 has Performed in-line its overall industry.
No data currently available

2X1 Sales Forecast

Next quarter’s sales forecast for 2X1 is €692.00K with a range of €0.00 to €1.40M. The previous quarter’s sales results were €0.00. 2X1 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 63.25% of the time in the same period. In the last calendar year 2X1 has Performed in-line its overall industry.
Next quarter’s sales forecast for 2X1 is €692.00K with a range of €0.00 to €1.40M. The previous quarter’s sales results were €0.00. 2X1 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 63.25% of the time in the same period. In the last calendar year 2X1 has Performed in-line its overall industry.

2X1 Stock Forecast FAQ

What is DE:2X1’s average 12-month price target, according to analysts?
Based on analyst ratings, Abivax SA’s 12-month average price target is 132.00.
    What is DE:2X1’s upside potential, based on the analysts’ average price target?
    Abivax SA has 34.97% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Abivax SA a Buy, Sell or Hold?
          Abivax SA has a consensus rating of Moderate Buy, which is based on 1 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Abivax SA’s share price target?
            The average share price target for Abivax SA is 132.00. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €132.00 ,and the lowest forecast is €132.00. The average share price target represents 34.97% Increase from the current price of €97.8.
              What do analysts say about Abivax SA?
              Abivax SA’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.
                How can I buy shares of Abivax SA?
                To buy shares of DE:2X1, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.